Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 915

1.

Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.

Roboz GJ, Ritchie EK, Curcio T, Provenzano J, Carlin R, Samuel M, Wittenberg B, Mazumdar M, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ.

Cancer. 2008 Nov 1;113(9):2504-11. doi: 10.1002/cncr.23855.

2.

Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia.

Roboz GJ.

Semin Hematol. 2008 Jul;45(3 Suppl 2):S22-4. doi: 10.1053/j.seminhematol.2008.07.005. Review.

PMID:
18760707
4.

Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.

Roboz GJ, Ritchie EK, Curcio T, Samuel M, Provenzano J, Segovia J, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ.

Leuk Res. 2011 Apr;35(4):522-5. doi: 10.1016/j.leukres.2010.09.010. Epub 2010 Oct 16.

PMID:
20956016
5.

Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.

Kalaycio M, Pohlman B, Elson P, Lichtin A, Hussein M, Tripp B, Andresen S.

Am J Clin Oncol. 2001 Feb;24(1):58-63.

PMID:
11232951
6.

Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.

Saito K, Nakamura Y, Aoyagi M, Waga K, Yamamoto K, Aoyagi A, Inoue F, Nakamura Y, Arai Y, Tadokoro J, Handa T, Tsurumi S, Arai H, Kawagoe Y, Gunnji H, Kitsukawa Y, Takahashi W, Furusawa S.

Int J Hematol. 2000 Apr;71(3):238-44.

PMID:
10846828
7.

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.

Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A; German AML Cooperative Group.

J Clin Oncol. 2003 Dec 15;21(24):4496-504.

PMID:
14673036
8.

Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.

Pigneux A, Harousseau JL, Witz F, Sauvezie M, Bene MC, Luquet I, Hunault-Berger M, Recher C, Lioure B, Himberlin C, Escoffre-Barbe M, Berthou C, Lissandre S, Fegueux N, Cahn JY, Jourdan E, Dreyfus F, Reiffers J, Milpied N, Ifrah N.

J Clin Oncol. 2010 Jun 20;28(18):3028-34. doi: 10.1200/JCO.2009.26.4648. Epub 2010 May 17.

PMID:
20479424
10.

Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland.

Lerch E, Espeli V, Zucca E, Leoncini L, Scali G, Mora O, Bordoni A, Cavalli F, Ghielmini M.

Tumori. 2009 May-Jun;95(3):303-10.

11.

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.

Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E.

Cancer. 2006 Mar 1;106(5):1090-8.

12.

The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.

Wrzesien-Kus A, Robak T, Jamroziak K, Wierzbowska A, Dmoszynska A, Adamczyk-Cioch M, Kuliczkowski K, Mazur G, Holowiecki J, Konopka L, Maj S, Marianska B, Zawilska K; Polish Acute Leukemia Group (PALG) phase II study.

Neoplasma. 2002;49(6):405-11.

PMID:
12584589
13.

A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.

Alymara V, Tzouvara E, Vartholomatos G, Chaidos A, Tsiara S, Bourantas KL.

J Exp Clin Cancer Res. 2004 Sep;23(3):447-54.

PMID:
15595635
14.

[Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia].

Zhang GC, Zheng D, Li QH, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.

Ai Zheng. 2004 Apr;23(4):430-4. Chinese.

PMID:
15087033
15.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.

Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20.

PMID:
18571721
16.

Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.

Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B.

Ann Hematol. 2008 May;87(5):361-7. Epub 2007 Dec 12.

PMID:
18074133
17.

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.

Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E.

Leuk Res. 2005 Jun;29(6):649-52. Epub 2005 Apr 1.

PMID:
15863204
18.

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.

Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Ludwig WD, Serve H, Reichle A, Peceny R, Oruzio D, Schmid C, Schiel X, Hentrich M, Sauerland C, Unterhalt M, Fiegl M, Kern W, Buske C, Bohlander S, Heinecke A, Baurmann H, Beelen DW, Berdel WE, Büchner T, Hiddemann W.

Blood. 2009 Apr 23;113(17):3903-10. doi: 10.1182/blood-2008-07-162842. Epub 2009 Jan 8.

19.

Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.

Fukushima T, Kawabata H, Sawaki T, Satoh T, Nakamura T, Iwao H, Nakajima A, Sakai T, Miki M, Fujita Y, Tanaka M, Kawanami T, Masaki Y, Okazaki T, Umehara H.

Anticancer Res. 2012 Apr;32(4):1347-53.

PMID:
22493369
20.

Supplemental Content

Support Center